An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Trial Profile

An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Nivolumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate057
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 15 Sep 2017 Results of pooled analysis of this trial and three other trials (70036762, 700220443, 700225594) published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 12 Sep 2017 Updated results based on a minimum follow-up of 3 years from CheckMate 017 and 057 studies,presented at the 42nd European Society for Medical Oncology Congress
    • 08 Sep 2017 Results from this trial will be presented at the European Society for Medical Oncology 2017 Congress, according to a Bristol-Myers Squibb media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top